


## ABSTRACT

**Background:** In many tumors, extracellular adenosine contributes to an immunosuppressed tumor microenvironment via activation of the A<sub>2a</sub> receptor (A<sub>2a</sub>R) and A<sub>2b</sub> receptor (A<sub>2b</sub>R) expressed on intratumoral immune cells. AB928 is a selective, small-molecule A<sub>2a</sub>R and A<sub>2b</sub>R antagonist with the ability to potently block the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment. Preclinically, combining adenosine receptor inhibition with either chemotherapy or anti-programmed cell death-1 (PD-1) resulted in greater tumor control in mouse models, suggesting AB928 may have synergistic activity when paired with either chemotherapy or checkpoint inhibitors in oncology patients. A phase 1 study with AB928 in healthy volunteers has been completed.

**Methods:** A phase 1/1b, open-label, dose-escalation (3+3 design) study is evaluating the safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of AB928 in combination with mFOLFOX in patients with gastrointestinal malignancies. Patients are eligible if they have histologically confirmed gastroesophageal cancer (GEC) or colorectal cancer (CRC) that is metastatic or locally advanced and unresectable for which no alternative or curative therapy exists, or standard therapy is not considered appropriate by the participant and treating physician. Patients must have received ≤5 lines of prior therapies and must not have received prior oxaliplatin treatment, except those who have received prior oxaliplatin-based therapy as the most recent regimen in the adjuvant setting if completed ≥6 months prior to enrollment. AB928 is administered orally once daily at a starting dose of 75 mg (Cohort 1) escalating to 150 mg (Cohort 2) and 200 mg (Cohort 3), and mFOLFOX is administered at the standard regimen (oxaliplatin 85 mg/m<sup>2</sup> intravenously [IV] every 2 weeks [Q2W], leucovorin 400 mg/m<sup>2</sup> IV Q2W, and 5-fluorouracil [5-FU] 400 mg/m<sup>2</sup> IV bolus + 2400 mg/m<sup>2</sup> [continuous 46-hour infusions on Days 1 and 2]). Intermediate AB928 doses may be evaluated based on data from cohorts that have been explored. Doses that have exceeded the maximum tolerated dose (MTD) will not be evaluated. Following identification of the recommended phase 2 dose (RP2D) of AB928 and mFOLFOX during dose escalation, each tumor cohort (GEC and CRC) may be expanded to further evaluate the combination. The primary endpoint is safety/tolerability and secondary endpoints are PK, PD (receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets), and clinical activity (objective response rate [ORR], duration of response, disease control rate [DCR; complete response (CR), partial response (PR), or stable disease (SD) for >6 months], and progression-free survival [PFS] per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1, and overall survival). The study is recruiting.


## BACKGROUND

- The accumulation of adenosine, generated through hydrolysis of extracellular adenosine monophosphate (AMP) by the ectonucleotidase CD73, is a key strategy exploited by tumors to escape immunosurveillance (Figure 1)<sup>1,2</sup>
- Adenosine's suppressive effects on immune cells are driven primarily by 2 of the 4 adenosine receptors, A<sub>2a</sub>R and A<sub>2b</sub>R<sup>3</sup>
  - This effect is mediated by increased cyclic AMP (cAMP) levels and phosphorylation of cAMP response element binding protein (CREB)
- Pharmacological inhibition of the effects of adenosine has recently generated much interest in immuno-oncology, but thus far, only A<sub>2a</sub>R antagonists, initially developed for central nervous system indications,<sup>4</sup> are being studied in oncology




**Figure 1. Adenosine-mediated immune suppression**

- AB928 is a novel, selective, small-molecule A<sub>2a</sub>R/A<sub>2b</sub>R antagonist designed to potently block the immunosuppressive effects of high concentrations of adenosine in the tumor microenvironment
- AB928 differs from other known A<sub>2a</sub>R antagonists based on its dual mode of action, its minimal loss of potency due to nonspecific binding to plasma proteins, and its lack of penetration through a healthy blood-brain barrier
- In mouse models, combining adenosine receptor inhibition with either chemotherapy (Figure 2) or anti-PD-1 resulted in greater tumor control, suggesting AB928 may have synergistic activity when combined with either chemotherapy or checkpoint inhibitors in cancer patients<sup>5</sup>
  - This is supported by the literature showing that cancer cells treated with chemotherapy induce immunogenic cell death, characterized by upregulation of CD39/CD73 leading to enhanced adenosine generation



**Figure 2. Tumor control with AB928 + doxorubicin (A) or oxaliplatin (B) in mouse model**  
\*\*p<0.01 AB928 + chemotherapy vs chemotherapy alone

- A phase 1 study of AB928 in healthy volunteers has been completed<sup>6</sup>
  - This placebo-controlled study with single-ascending and multiple-ascending dose arms assessed AB928 doses between 10 and 200 mg once daily and 100 mg twice
  - AB928 was well tolerated and no safety concern was identified
    - All adverse events (AEs) were Grade 1/2; there were no DLTs, serious AEs, or AEs resulting in study drug discontinuation
  - The PK profile of AB928 was linear and dose-proportional, and a clear PK/PD correlation was demonstrated (Figure 3)
  - AB928 plasma levels ≥1 μM were associated with ≥90% adenosine receptor inhibition



**Figure 3. PK/PD correlation in AB928-dosed subjects measured by pCREB inhibition**

- Four clinical studies of AB928 in combination with other agents have been initiated in cancer patients in Australia and United States (Table 1)
  - The study described herein (AB928CSP0003) is assessing the safety/tolerability, PK, PD, and clinical activity of AB928 in combination with standard of care (SOC) mFOLFOX in patients with GEC or CRC

**Table 1. Ongoing AB928 combination studies in oncology**

Study Number	Combination	Tumor Type
AB928CSP0002	AB928 + PLD (SOC)	TNBC or Ovarian
AB928CSP0003	AB928 + mFOLFOX (SOC)	GEC or CRC
AB928CSP0004	AB122 (240 mg Q2W) AB928 + Carbo/Pem + Pembro (SOC) AB928 + Carbo/Pem	NSCLC
AB928CSP0005	AB928 + AB122 (240 mg Q2W)	Solid tumors

## METHODS

### Patients

#### Key Inclusion Criteria


- Male or female patients ≥18 years of age
- Dose escalation:** Histologically confirmed GEC or CRC that is metastatic or locally advanced and unresectable for which no alternative/curative therapy exists or standard therapy is not considered appropriate by patient and treating physician
- Dose expansion:** Histologically confirmed GEC or CRC that is metastatic or locally advanced and unresectable for which no alternative/curative therapy exists or standard therapy is not considered appropriate by patient and treating physician
- ≥1 measurable lesion per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

#### Key Exclusion Criteria

- Live vaccines within 4 weeks of study drug initiation
- Pregnant or breastfeeding
- Active or prior autoimmune disease requiring systemic treatment
- Prior chemotherapy, targeted small-molecule therapy, or radiotherapy within 4 weeks of study drug initiation or has not recovered from AEs resulting from previous agents

## Study Design and Treatment

- This is a phase 1/1b, open-label, dose-escalation, dose-expansion study (Figure 4)
- Dose escalation:** Escalating doses of AB928 (75 mg [starting dose, Cohort 1], 150 mg [Cohort 2], and 200 mg [Cohort 3]) administered orally once daily in combination with mFOLFOX (oxaliplatin, leucovorin, 5-FU) will be assessed based on a 3+3 design, including a DLT evaluation period
  - Intermediate AB928 doses may be evaluated based on data from cohorts that have been explored
  - Doses that have exceeded the MTD will not be evaluated
  - Up to 18 patients, depending on the toxicities observed, may be evaluated
- Dose expansion:** The dose of AB928 to be used in the dose-expansion phase will be determined based on findings from the dose-escalation phase; mFOLFOX will be administered according to standard treatment guidelines
  - Each tumor expansion cohort will consist of 15 to 40 patients



**Figure 4. Study schema**

## Endpoints

### Primary Endpoint

- Safety: Incidence of AEs and DLTs, and changes from baseline in vital signs, clinical laboratory parameters, physical examination findings, ECOG performance status, and electrocardiogram

### Secondary Endpoints

- Serum concentration and PK parameters for AB928 combined with mFOLFOX
- Receptor occupancy in peripheral blood and immunomodulatory activity in select immune subsets for AB928 combined with mFOLFOX
- Clinical activity: ORR, duration of response, DCR (defined as CR, PR, or SD for >6 months), and PFS per RECIST v1.1, and overall survival

## Statistical Analysis

- Summary statistics will be provided for AEs, serious AEs, AE severity, and relationship to study drug
- PK parameters will be estimated using noncompartmental methods
- ORR and DCR will be estimated by the proportion of patients with objective response and disease control, respectively, and their 95% confidence intervals will be estimated using the exact binomial method
- Time-to-event endpoints will be summarized using the Kaplan-Meier method
- Interim analyses for futility will be conducted for each expansion cohort that has enrolled ≥15 patients who are evaluable for disease assessment

## Trial Status

- Enrollment is ongoing

## REFERENCES

- Allard B, et al. Immunol Rev 2017;276:121-44.
- Picher M, et al. J Biol Chem 2003;278:13468-79.
- Fredholm BB, et al. Pharmacol Rev 2011;63:1-34.
- Dungo R, Deeks ED. Drugs 2013;73:875-82.
- Walters MJ, et al. Cancer Res 2018;78(13 suppl):abstract 5556.
- Seitz L, et al. Ann Oncol 2018;29(suppl 8):abstract 1880P.